Actinium Pharmaceuticals Shareholders Urged to Join Class Action by Deadline of May 27, 2025

Class Action Alert: Actinium Pharmaceuticals Shareholders

The Gross Law Firm has announced an urgent notification for shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), highlighting the necessity for affected individuals to consider joining a class action lawsuit. This legal action has a deadline of May 27, 2025, compelling investors to act swiftly if they wish to seek potential recovery for their losses.

Key Details of the Class Action

Shareholders who acquired Actinium shares between October 31, 2022, and August 2, 2024, are particularly encouraged to reach out. The allegations centered around the company’s failure to disclose critical information regarding its Phase 3 Sierra trial for the targeted radiotherapy, Iomab-B, raises serious concerns regarding the reliability of the information previously presented to the public and investors.

Allegations Against Actinium Pharmaceuticals

The complaint indicates that during the specified class period, the defendants provided materially misleading statements or neglected to disclose that:
1. Data from the Sierra trial was unlikely to meet the FDA guidelines necessary for acceptance and approval of the Iomab-B Biologics License Application (BLA).
2. Further analyses presented to address the shortcomings of the Sierra trial’s overall survival data were insufficient to convince the FDA of the product’s validity.
3. Consequently, the expectations for the Iomab-B BLA being reviewed or approved were overly optimistic.
4. This lack of transparency about the company's situation led to inflated perceptions concerning their business prospects and stability.

Shareholders are advised that registering as plaintiffs is essential for participation in the recovery process. However, becoming a lead plaintiff is not mandatory to benefit from the lawsuit’s outcomes.

Next Steps for Shareholders

Acting quickly is crucial—as registration must occur before May 27, 2025. Interested shareholders can register their information through the provided link, which will subsequently enroll them in a portfolio monitoring system to keep them informed about the progress of the case. This service ensures that investors remain updated throughout the trial’s evolution, offering peace of mind amid uncertainties.

Contact Information
For those interested, The Gross Law Firm provides contact details for immediate inquiries. The firm is dedicated to advocating for the rights of investors who have suffered losses due to deceptive practices and false statements from companies.

In addition, the firm emphasizes its commitment to responsible business practices and corporate accountability—making it an ally for investors nationwide.

Conclusion

With a growing focus on investor rights, this class action brings to light the crucial need for transparency from public companies. Shareholders of Actinium Pharmaceuticals are urged not to delay their involvement to ensure they have a voice in this legal pursuit against the alleged negligence by the company. As the deadline approaches, timely registration becomes ever more critical.

Contact The Gross Law Firm